Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system

Brain, Behavior, and Immunity

Volumn 50, Issue , 2015, Pages 155-165

  Salinas Tejedor, Laura ^a,b   Berner, Gabriel ^a   Jacobsen, Kristin ^a   Gudi, Viktoria ^a,b   Jungwirth, Nicole ^b,c   Hansmann, Florian ^b,c   Gingele, Stefan ^a   Prajeeth, Chittappen K ^a   Baumgärtner, Wolfgang ^b,c   Hoffmann, Andrea ^a   Skripuletz, Thomas ^a   Stangel, Martin ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Corpus callosum; Cuprizone; Intraventricular; MS; MSC

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS CALLOSUM; CUPRIZONE-INDUCED DEMYELINATION; DEMYELINATION; DOG; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROGLIA; MOUSE; NERVE REGENERATION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PERIPHERAL IMMUNE SYSTEM; PRIORITY JOURNAL; REMYELINIZATION; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MESENCHYMAL STROMA CELL; MULTIPLE SCLEROSIS; MYELIN SHEATH; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CUPRIZONE;

ANIMALS; CORPUS CALLOSUM; CUPRIZONE; DOGS; HUMANS; IMMUNE SYSTEM; INJECTIONS, INTRAVENTRICULAR; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICROGLIA; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA;

EID: 84945543444     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.06.024     Document Type: Article

References (42)

1. Bénardais K., Kotsiari A., Skuljec J., Koutsoudaki P.N., Gudi V., Singh V., Vulinović F., Skripuletz T., Stangel M. Cuprizone [bis(cyclohexylidenehydrazide)] is selectively toxic for mature oligodendrocytes. Neurotox. Res. 2013, 24:244-250.
2. Bénardais K., Gudi V., Gai L., Neßler J., Singh V., Prajeeth C.K., Skripuletz T., Stangel M. Long-term impact of neonatal inflammation on demyelination and remyelination in the central nervous system. Glia 2014, 62:1659-1670.
3. Bhatt A., Fan L.W., Pang Y. Strategies for myelin regeneration: lessons learned from development. Neural. Regen. Res. 2014, 9:1347-1350.
4. Chen P.M., Yen M.L., Liu K.J., Sytwu H.K., Yen B.L. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J. Biomed. Sci. 2011, 18:49.
5. De Bakker E., Van Ryssena B., De Schauwerb C., Meyerc E. Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man. Vet. Q. 2013, 33:225-233.
6. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop Dj., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. El-Akabawy G., Rashed L.A. Beneficial effects of bone marrow-derived mesenchymal stem cell transplantation in a non-immune model of demyelination. Ann. Anat. 2015, 198:11-20.
8. Gao J., Dennis J.E., Muzic R.F., Lundberg M., Caplan A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169:12-20.
9. Gudi V., Moharregh-Khiabani D., Skripuletz T., Koutsoudaki P.N., Kotsiari A., Skuljec J., Trebst C., Stangel M. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res. 2009, 1283:127-138.
10. Gudi V., Škuljec J., Yildiz Ö., Frichert K., Skripuletz T., Moharregh-Khiabani D., Voss E., Wissel K., Wolter S., Stangel M. Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS One 2011, 6(7):e22623.
11. Gudi V., Gingele S., Skripuletz T., Stangel M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front. Cell. Neurosci. 2014, 8:73.
12. Hedayatpour A., Ragerdi I., Pasbakhsh P., Kafami L., Atlasi N., Pirhajati Mahabadi V., Ghasemi S., Reza M. Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis. Cell J. 2013, 15:142-151.
13. Jaramillo-Merchán J., Jones J., Ivorra J.L., Pastor D., Viso-León M.C., Armengól J.A., Moltó M.D., Geijo-Barrientos E., Martínez S. Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model. Cell Death. Dis. 2013, 4:e779.
14. Kassis I., Grigoriadis N., Gowda-Kurkalli B., Mizrachi-Kol R., Ben-Hur T., Slavin S., Abramsky O., Karussis D. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch. Neurol. 2008, 65:753-761.
15. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
16. Lanz T.V., Opitz C.A., Ho P.P., Agrawal A., Lutz C., Weller M., Mellor A.L., Steinman L., Wick W., Platten M. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev. 2010, 19:657-668.
17. Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia 2014, 62:1816-1830.
18. Lindner M., Heine S., Haastert K., Garde N., Fokuhl J., Linsmeier F., Grothe C., Baumgärtner W., Stangel M. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol. Appl. Neurobiol. 2008, 34:105-114.
19. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:107-116.
20. Morando S., Vigo T., Esposito M., Casazza S., Novi G., Principato M.C., Furlan R., Uccelli A. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res. Ther. 2012, 3:3.
21. Nessler J., Bénardais K., Gudi V., Hoffmann A., Salinas Tejedor L., Janßen S., Prajeeth C.K., Baumgärtner W., Kavelaars A., Heijnen C.J., van Velthoven C., Hansmann F., Skripuletz T., Stangel M. Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination. PLoS One 2013, 8:e69795.
22. Odoardi F., Sie C., Streyl K., Ulaganathan V.K., Schläger C., Lodygin D., Heckelsmiller K., Nietfeld W., Ellwart J., Klinkert W.E., Lottaz C., Nosov M., Brinkmann V., Spang R., Lehrach H., Vingron M., Wekerle H., Flügel-Koch C., Flügel A. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488:675-679.
23. Patel A.N., Genovese J. Potential clinical applications of adult human mesenchymal stem cell (Prochymal(R)) therapy. Stem Cells Cloning 2011, 4:61-72.
24. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, New York.
25. Prajeeth C.K., Löhr K., Floess S., Zimmermann J., Ulrich R., Gudi V., Beineke A., Baumgärtner W., Müller M., Huehn J., Stangel M. Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. Brain Behav. Immun. 2014, 37:248-259.
26. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., Yuan S., Young Y.K., Boivin M.N., Forner K., Basik M., Galipeau J. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 2009, 182:5994-6002.
27. Schack L.M., Noack S., Weist R., Jagodzinski M., Krettek C., Buettner M., Hoffmann A. Analysis of surface protein expression in human bone marrow stromal cells: new aspects of culture-induced changes, inter-donor differences and intracellular expression. Stem Cells Dev. 2013, 22:3226-3235.
28. Schmidt T., Awad H., Slowik A., Beyer C., Kipp M., Clarner T. Regional heterogeneity of cuprizone-induced demyelination: topographical aspects of the midline of the corpus callosum. J. Mol. Neurosci. 2013, 49:80-88.
29. Screven R., Kenyon E., Myers M.J., et al. Immunophenotype and gene expression profile of mesenchymal stem cells derived from canine adipose tissue and bone marrow. Vet. Immunol. Immunopathol. 2014, 161:21-31.
30. Skripuletz T., Lindner M., Kotsiari A., Garde N., Fokuhl J., Linsmeier F., Trebst C., Stangel M. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am. J. Pathol. 2008, 172:1053-1061.
31. Skripuletz T., Gudi V., Hackstette D., Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol. Histopathol. 2011, 26:1585-1597.
32. Skripuletz T., Miller E., Grote L., Gudi V., Pul R., Voss E., Skuljec J., Moharregh-Khiabani D., Trebst C., Stangel M. Lipopolysaccharide delays demyelination and promotes oligodendrocyte precursor proliferation in the central nervous system. Brain Behav. Immun. 2011, 25:1592-1606.
33. Skripuletz T., Hackstette D., Bauer K., Gudi V., Pul R., Voss E., Berger K., Kipp M., Baumgärtner W., Stangel M. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 2013, 136:147-167.
34. Skripuletz T., Manzel A., Gropengießer K., Schäfer N., Gudi V., Singh V., Salinas Tejedor L., Jörg S., Hammer A., Voss E., Vulinovic F., Degen D., Wolf R., Lee D.H., Pul R., Moharregh-Khiabani D., Baumgärtner W., Gold R., Linker R.A., Stangel M. Pivotal role of choline metabolites in remyelination. Brain 2015, 138:398-413.
35. Sung J.H., Yang H.M., Park J.B., Choi G.S., Joh J.W., Kwon C.H., Chun J.M., Lee S.K., Kim S.J. Isolation and characterization of mouse mesenchymal stem cells. Transp. Proc. 2008, 40:2649-2654.
36. Tanaka T., Yoshida S. Mechanisms of remyelination: recent insight from experimental models. Biomol. Concepts 2014, 5:289-298.
37. Tondreau T., Dejeneffe M., Meuleman N., Stamatopoulos B., Delforge A., Martiat P., Bron D., Lagneaux L. Gene expression pattern of functional neuronal cells derived from human bone marrow mesenchymal stromal cells. BMC Genomics 2008, 9:166.
38. Torkildsen O., Brunborg L.A., Myhr K.M., Bø L. The cuprizone model for demyelination. Acta Neurol. Scand. Suppl. 2008, 188:72-76.
39. Uccelli A., Prockop D.J. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. Curr. Opin. Immunol. 2010, 22:768-774.
40. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
41. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
42. Zhang J., Li Y., Chen J., Cui Y., Lu M., Elias S.B., Mitchell J.B., Hammill L., Vanguri P., Chopp M. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp. Neurol. 2005, 195:16-26.